New indication promise for Novo Nordisk drug NovoSeven  

2003.12.23
Phase 2 studies of the Danish healthcare company’s drug NovoSeven show surprising effectiveness in reducing massive bleeding

Novo Nordisk has announced initial results from its phase 2 studies of NovoSeven in trauma patients, which show that the drug is surprisingly effective in reducing loss of blood in connection with severe haemorrhages. Patients receiving treatment with NovoSeven needed significantly less blood transfusion than patients receiving conventional treatment.

 

NovoSeven is currently used for the treatment of haemophilia and is Novo Nordisk’s second most important business area after diabetes. The pharmaceutical company will now conduct further tests to gain an additional indication for NovoSeven as a trauma treatment. If all goes according to plan the product should be marketed by 2007. The news is reported by national daily newspaper Jyllands-Posten.

 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×